Biorestorative Therapies News

BioRestorative Therapies Signs Five-Year Supply Agreement With Cartessa; BioRestorative To Supply Cartessa With Finished Vials Of Commercial Product Sold Under Chronos ExoCR Brand

BioRestorative Therapies Signs Five-Year Supply Agreement With Cartessa; BioRestorative To Supply Cartessa With Finished Vials Of Commercial Product Sold Under Chronos ExoCR Brand

BenzingaMay 15 21:05

BioRestorative Therapies (NASDAQ:BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market

AccesswireMay 15 21:02

Earnings Call Summary | Biorestorative Therapies(BRTX.US) Q1 2024 Earnings Conference

The following is a summary of the BioRestorative Therapies, Inc. (BRTX) Q1 2024 Earnings Call Transcript:Financial Performance:BioRestorative Therapies ended Q1 2024 with a solid financial position, h

Futu NewsMay 15 14:07 · Conference Call

BioRestorative Therapies, Inc. (BRTX) Q1 2024 Earnings Call Transcript

BioRestorative Therapies, Inc. (BRTX) Q1 2024 Earnings Call Transcript

Earnings Call TranscriptsMay 15 07:08

BioRestorative Therapies Provides First Quarter 2024 Business Update

MELVILLE, N.Y., May 14, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today provided

GlobeNewswireMay 15 04:10

Buy Rating on BioRestorative Therapies for Innovative Obesity Treatment Approach

TipRanksMay 10 02:15

BioRestorative Therapies Announced Its Development Of A Novel Exosome-based Biologic Program Targeting Obesity

BioRestorative Therapies Announced Its Development Of A Novel Exosome-based Biologic Program Targeting Obesity

BenzingaMay 8 19:41

BioRestorative Therapies Enhances Preclinical Metabolic Program With a Novel Exosome-Based Biologic Targeting Obesity

— New therapeutic candidate developed using Company's patented ThermoStem platform — — Candidate has potential to serve as an adjuvant to existing pharmaceuticals that are FDA approved and marketed to

GlobeNewswireMay 8 19:30

Buy Rating on BioRestorative Therapies: Innovative Cell-based Therapies and Strategic Growth Opportunities

TipRanksMay 3 00:15

Analysts Have Conflicting Sentiments on These Healthcare Companies: United Therapeutics (UTHR) and BioRestorative Therapies (BRTX)

TipRanksMay 3 00:10

BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

- Company to provide update on exciting new commercial agreement, as well as Phase 2 clinical trial in Spine and preclinical development program in Obesity - MELVILLE, N.Y., April 30, 2024 (GLOBE NEWSWIRE) --

GlobeNewswireMay 1 04:15

BioRestorative Therapies Announces Transformative Commercial Agreement With Cartessa, a Global Leader in Medical Aesthetics Technology

— Leading regenerative medicine and aesthetics innovators collaborate to build a vertically integrated, best-in-class biocosmeceutical platform — — Exclusive, five (5)-year agreement includes BioRestorative

GlobeNewswireApr 30 19:30

Optimistic Outlook for BioRestorative Therapies Backed by Clinical and Strategic Advances

TipRanksApr 18 04:05

Biotech Catches Major Premarket Bid Following FDA Clearance

YolowireApr 16 22:07

BioRestorative Gains as FDA Clears Amendment to Study on Cell Therapy Candidate

Seeking AlphaApr 16 21:53

Market-Moving News for April 16th

CGEM: 23% | Cullinan Therapeutics To Pursue Development Of CLN-978 In Autoimmune Diseases, With Systemic Lupus Erythematosus As First Indication; Discontinued Enrollment In Its B-NHL Study To Focus On

BenzingaApr 16 20:36

Why BioRestorative Therapies Is Rising In Pre-market?

RTTNewsApr 16 20:15

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

GainersDynatronics (NASDAQ:DYNT) stock rose 84.9% to $0.69 during Tuesday's pre-market session. The company's market cap stands at $3.3 million. BioRestorative Therapies (NASDAQ:BRTX) shares rose 23.4

BenzingaApr 16 20:07

BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment

BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the U.S. Food and Drug Administration ("FDA") has cleared an important amendment to the protocol of the ongoing Phase 2 study investigating the use of BRTX-100, the Company's lead cell therapy candidate, in treating chronic lumbar disc disease ("cLDD").

GlobeNewswireApr 16 19:45

10 Micro-Cap Healthcare Stocks Insiders Are Buying

Yahoo FinanceApr 15 03:00